Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis

• Autores principales: Tingli Guo (Autor), Wenhui Yan (Autor), Xin Cui (Autor), Na Liu (Autor), Xiaotong Wei (Autor), Yuzhuo Sun (Autor), KeXin Fan (Autor), Jieyun Liu (Autor), Yuanyuan Zhu (Autor), Zhuanzhuan Wang (Autor), Yilei Zhang (Autor), Lina Chen (Autor)
• Formato: Libro
• Publicado: BMC, 2023-09-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of type 2 diabetes mellitus (T2DM). The pathogenesis of NAFLD involves multiple biological changes, including insulin resistance, oxidative stress, inflammation, as well as genetic and environmental...